论文部分内容阅读
目的:了解医疗机构诊断的丙型肝炎（简称“丙肝”）病例的诊断类型、疾病进展及治疗等情况。方法:在全国部分地区的二、三级医院设立监测哨点，对在哨点医院2017-2019年连续3年就诊中传染病报告的丙肝病例进行调查，了解其一般人口学特征、丙肝诊断、肝纤维化程度及治疗等情况。采用χn 2检验及χn 2趋势检验对其诊断、治疗等情况及有关因素进行分析。n 结果:3年共调查丙肝病例16 241例，其中临床诊断病例7 538例（占46.41%），确诊丙肝病例8 703例（占53.59%）；确诊病例中，急性60例（占0.69%），慢性8 643例（占99.31%）。3年间肝病相关科室诊断病例的占比由62.23%下降至40.01%,而非肝病的内科及外科病例占比由不足30%提升至接近60%。二级医院确诊病例比例（26.27%）显著低于三级医院（62.48%），差异有统计学意义（χn 2 = 1 594.833，n P < 0.001），不同地区确诊比例也存在差异（ n P值均 3.25的病例占35.78%，且该比例随年龄增加趋势明显（χn 2趋势= 1 159.624，n P < 0.001）。抗病毒治疗比例平均不足10%，二级医院抗病毒治疗比例极低（2.13%）；但单纯保肝治疗的比例从2017年的30.40%下降到2019年11.14%，差异有统计学意义（ n P < 0.001）。n 结论:医疗机构就诊人群丙肝筛查发现力度逐年增加，但仅半数左右病例可以确诊，二级医院确诊能力尤其不足。确诊病例中绝大多数为慢性丙肝病例，肝纤维化指标异常者超过1/3，且该比例随年龄增加。丙肝抗病毒治疗比例低，二级医院远低于三级医院。亟需提高医患双方对丙肝的重视，加强丙肝确诊能力，提高丙肝抗病毒治疗覆盖面。“,”Objective:To understand the hepatitis C diagnosis type, progression and treatment in medical institutions.Methods:Monitoring posts were set up in the secondary and tertiary-level hospitals in some parts of the country. Reported infectious diseases cases of hepatitis C in sentinel hospitals during the three consecutive years from 2017 to 2019 were investigated to understand their general demographic characteristics, diagnosis, liver fibrosis degree, and treatment. The diagnosis, treatment and related factors were analyzed by chi square test and trend.Results:A total of 16 241 cases of hepatitis C were investigated in three years. Among them, 7 538 cases were clinically diagnosed (46.41%) and 8703 cases (53.59%) were confirmed as hepatitis C. Among the confirmed cases, 60 cases (0.69%) were acute and 8643 cases (99.31%) were chronic. In the past three years, the proportion of cases diagnosed by liver diseases related departments decreased from 62.23% to 40.01%, while the proportion of medical and surgical cases of non-liver diseases increased from less than 30% to nearly 60%. The proportion of confirmed cases in secondary hospitals (26.27%) was significantly lower than that in tertiary hospitals (62.48%), and the difference was statistically significant (n χ2 = 1594.833, n P < 0.001). There were also differences in the proportion of confirmed cases in different regions ( n P 3.25 accounted for 35.78%, and the proportion was increased significantly with age ( n χ2 trend = 1159.624, n P < 0.001). The average proportion of antiviral treatment was less than 10%, and the proportion of antiviral treatment in secondary hospitals was very low (2.13%); however, the proportion of liver-protective monotherapy treatment was decreased from 30.40% in 2017 to 11.14% in 2019, and the difference was statistically significant ( n P < 0.001).n Conclusion:The large-scale screening of hepatitis C by medical institutions is increasing year by year, but only about half of the cases can be diagnosed, and the diagnostic capacity of secondary hospitals is particularly unsatisfactory. Most of the confirmed cases are chronic hepatitis C, and more than one third of them have abnormal liver fibrosis indicators, and the proportion increases with age. The proportion of antiviral treatment for hepatitis C is lower in secondary than tertiary-level hospitals. Therefore, there is an urgent need to raise the attention of both parties (doctors and patients) to enhance diagnostic capabilities and expand the coverage of antiviral treatment for hepatitis C.